Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC Begins Construction of New Head Office Building, Expects Completion in January 2015
July 4, 2013
- Generic Industry Needs to Produce 30 Billion More Tablets to Meet 60% Generic Share Goal: Sawai President
July 4, 2013
- Out-Licensed OAB Treatment Imidafenacin Launched in South Korea: Kyorin Holdings
July 4, 2013
- Low-Dose Lunabell Approved
July 4, 2013
- Manipulation of BMI Data in Kobayashi Pharmaceutical’s Anti-Obesity Drug Clinical Study Suspected
July 3, 2013
- Sandoz to Ratchet Up Promotions for General Practitioners, Dispensing Pharmacies
July 3, 2013
- Latuda Approved for Major Depressive Episodes Associated with Bipolar I Disorder in the US: DSP
July 3, 2013
- Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
- DSP Adopts Tokyo-Osaka Two Head Office System
July 2, 2013
- Takeda Withdraws European MAA for Anemia Treatment Peginesatide Following Voluntary Recall in US
July 2, 2013
- Gout, Hyperuricemia Treatment Topiloric/Uriadec Tablets Approved: Fuji Yakuhin, Sanwa Kagaku
July 2, 2013
- Astellas’ US Affiliate Agensys to Codevelop ADC with Seattle Genetics
July 1, 2013
- Kyowa Kirin Files NDA for Sustained-Duration G-CSF KRN125, PEGylated Form of Gran
July 1, 2013
- Takeda President Executive Pay Reaches 300 Million Yen, Three Execs Receive Over 700 Million Yen
June 28, 2013
- Novartis Files Combination Drug for Parkinson’s Disease in Japan
June 28, 2013
- Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
- Reasons for Doctors’ Reluctance to Generic Name Prescribing is Time and Effort: CareNet Survey
June 28, 2013
- Tsumura Reports Record Profits through Intensified MR Activities to Educate Doctors about Kampo Medicine
June 28, 2013
- Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
June 27, 2013
- Shionogi Establishes New Chinese Subsidiary
June 27, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…